慢性透析启动时的肺炎球菌疫苗接种覆盖率及其与第一年死亡率的关系
研究基于法国REIN登记与SNIIRAM数据库,纳入2015年启动慢性透析的8294例患者,评估肺炎球菌疫苗接种覆盖率及与一年全因死亡率的关系。结果显示22.3%患者接种过至少一剂肺炎球菌疫苗,接种PCV13后序贯PPSV23或仅接种PCV13与一年死亡率降低独立相关。
要点
- 8294例透析启动患者中22.3%接种过至少一剂肺炎球菌疫苗。
- 接种PCV13序贯PPSV23者HR=0.37(95%CI 0.28-0.51),仅接种PCV13者HR=0.35(95%CI 0.19-0.65)。
- 仅接种PPSV23与一年死亡率无独立关联。
核心结论
- 接种PCV13后序贯PPSV23或仅接种PCV13,而非仅接种PPSV23,与透析启动患者一年死亡率降低独立相关。
研究设计与样本
- 研究数据来自两个法国前瞻性国家数据库(REIN登记和SNIIRAM),采用确定性链接方法合并。
- 纳入2015年所有启动慢性透析的患者,共8294例。
- 收集透析启动时健康状况、透析方式及透析启动前2年至后1年肺炎球菌疫苗处方数据。
- 采用单因素和多因素Cox比例风险模型评估一年全因死亡率。
主要发现
- 8294例患者中1849例(22.3%)接种至少一剂肺炎球菌疫苗:透析启动前接种542例(6.5%),启动后接种1307例(15.8%)。
- 接种方案构成:PCV13序贯PPSV23者938例(50.7%),仅接种PPSV23者650例(35.1%),仅接种PCV13者261例(14.1%)。
- 接种组较未接种组更年轻(平均66.5±14.8岁 vs 69.0±14.9岁,P≤0.001),肾小球肾炎比例更高(17.0% vs 11.0%,P≤0.001),紧急启动透析比例更低(27.2% vs 31.1%,P=0.001)。
- 多因素分析中,接种PCV13序贯PPSV23者死亡风险HR=0.37(95%CI 0.28-0.51),仅接种PCV13者HR=0.35(95%CI 0.19-0.65)。
关键数值与推荐
- 原文推荐透析患者接种肺炎球菌疫苗。
- 接种PCV13序贯PPSV23者HR=0.37(95%CI 0.28-0.51)。
- 仅接种PCV13者HR=0.35(95%CI 0.19-0.65)。
临床怎么用
- 原文推荐透析患者接种肺炎球菌疫苗。
- 作者结论认为接种PCV13后序贯PPSV23或仅接种PCV13与透析启动患者一年死亡率降低独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pneumococcal immunization is recommended in dialysis patients. We aimed to estimate pneumococcal vaccination coverage among patients who initiate dialysis in France, and its association with mortality. METHODS: Data were extracted from two prospective national databases, merged using a deterministic linkage method: renal epidemiology and information network (REIN) registry, which includes all patients on dialysis and kidney transplants recipients in France, and the national health insurance information system (SNIIRAM) which collects individual data on health expenditure reimbursement, including vaccines. We enrolled all patients who initiated chronic dialysis in 2015. Data on health status at dialysis initiation, dialysis modalities, and pneumococcal vaccine prescribed from 2 years before to 1 year after dialysis start were collected. Univariate and multivariate Cox proportional hazard models were used to assess one-year all-cause mortality. RESULTS: Among the 8,294 incident patients included, 1,849 (22.3 %) received at least one pneumococcal vaccine before (n = 542, 6.5 %), or after (n = 1,307, 15.8 %) dialysis start, as follows: 13-valent pneumococcal conjugated vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23), n = 938 (50.7 %); only PPSV23, n = 650 (35.1 %); or only PCV13, n = 261 (14.1 %). Vaccinated patients were younger (mean, 66.5 ± 14.8 years vs. 69.0 ± 14.9 years, P ≤ 0.001), more likely to suffer from glomerulonephritis (17.0 % vs. 11.0 %, P ≤ 0.001), and less likely to start dialysis in emergency (27.2 % vs. 31.1 %, P = 0.001). On multivariate analysis, patients who received PCV13 and PPSV23, or only PCV13 were less likely to die (respectively, HR = 0.37; 95 %CI 0.28-0.51, and HR = 0.35; 95 %CI 0.19-0.65). CONCLUSIONS: Pneumococcal immunization with PCV13 followed by PPSV23, or with PCV13 alone, but not with PPSV23 alone, is independently associated with decreased one year-mortality in patients who start dialysis.
引用
- Pierre É, Pladys A, Bayat-Makoei S, et al. Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year. Vaccine. 2023. PMID: 37179164. doi:10.1016/j.vaccine.2023.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。